AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage Therapy Response Rate
Number of subjects: 560
Study 8412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival after Relapse
Number of subjects: 560
Study 31135580 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids during consent process
Number of subjects: 64
Study 31135580 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 64
Study 30704298 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR using the self‐expanding CoreValve prosthesis
Number of subjects: 280
Study 30704298 — intervention group
Group type: COMPARATOR
Intervention: SAVR using any stented bioprostheses
Number of subjects: 280
Study 30704298 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 280
Study 30704298 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 280
Study 28403471 — intervention group
Group type: EXPERIMENTAL
Intervention: STARTS intervention (specialized focus on mood, weight, and stress)
Number of subjects: 300
Study 28403471 — intervention group
Group type: COMPARATOR
Intervention: SUPPORT intervention (comparison group)
Number of subjects: 300
Study 28403471 — intervention group
Group type: COMPARATOR
Intervention: SUPPORT intervention
Number of subjects: 300
Study 28403471 — intervention group
Group type: EXPERIMENTAL
Intervention: STARTS intervention
Number of subjects: 300
Study 25111040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 50
Study 25111040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24023022 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (full spinal flexion)
Number of subjects: 32
Study 24023022 — intervention group
Group type: COMPARATOR
Intervention: Group N (hips and back straightened)
Number of subjects: 32
Study 21311355 — intervention group
Group type: EXPERIMENTAL
Intervention: l-Arg HCl (30 g at 0.5 g·min(‐1))
Number of subjects: 7
Study 21311355 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control, CON)
Number of subjects: 7
Study 18294115 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic therapy
Number of subjects: 0
Study 18294115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anticholinergic therapy with alpha1‐antagonists
Number of subjects: 0
Study 17133492 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (3 million units 3 times every week for 48 weeks)
Number of subjects: 150
Study 17133492 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 14972218 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio frequency fistulotomy
Number of subjects: 100
Study 14972218 — intervention group
Group type: COMPARATOR
Intervention: Conventional fistulotomy
Number of subjects: 100
Study 10632419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) for the first two cycles and human menopausal gonadotropin (hMG) for the last two cycles (CCHH)
Number of subjects: 58
Study 10632419 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (hMG) for the first two cycles and clomiphene citrate (CC) for the last two cycles (HHCC)
Number of subjects: 58
Study 10632419 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 58
Study 10632419 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 58
Study 8923572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 60
Study 8923572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8923572 — intervention group
Group type: COMPARATOR
Intervention: No beverage
Number of subjects: 60
Study 1396075 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 52
Study 1396075 — intervention group
Group type: COMPARATOR
Intervention: routine anti-emetic regimen
Number of subjects: 52
Study 3986473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (Group I)
Number of subjects: 122
Study 3986473 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus metronidazole (Group II)
Number of subjects: 122
Study 27442606 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent And Caregiver Active Participation Toolkit
Number of subjects: 20
Study 27442606 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 27112041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fortification (EF) starting at 20 mL/kg/d
Number of subjects: 100
Study 27112041 — intervention group
Group type: COMPARATOR
Intervention: Delayed fortification starting at 100 mL/kg/d
Number of subjects: 100
Study 27112041 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fortification (EF)
Number of subjects: 100
Study 23911705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 23911705 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 227
Study 22507335 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine syrup
Number of subjects: 60
Study 22507335 — intervention group
Group type: COMPARATOR
Intervention: Cyproheptadine HCl solution
Number of subjects: 60
Study 20103550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment
Number of subjects: 0
Study 20103550 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemia treatment
Number of subjects: 0
Study 17087620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Change (LC)
Number of subjects: 508
Study 17087620 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 508
Study 14687172 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic gastritis
Number of subjects: 31
Study 14687172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin B12
Number of subjects: 31
Study 14687172 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-atrophic gastritis)
Number of subjects: 31
Study 11368128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulvar pain group
Number of subjects: 79
Study 11368128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 9273182 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (ICT) including three cycles of 5-fluorouracil (600 mg/m2/d), cisplatin (15 mg/m2/d), etoposide (50 mg/m2/d), hydroxyurea (1,500 mg/d)
Number of subjects: 46
Study 9273182 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and chest radiotherapy (CCRT) with cisplatin (20 mg/m2) and 5-fluorouracil (500 mg/m2) during radiotherapy
Number of subjects: 46
Study 9273182 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to ICT
Number of subjects: 46
Study 9273182 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders to ICT
Number of subjects: 46
Study 9273182 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 46
Study 8077090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (125 mg, 1 or 2 tablets every 8 h for 48 h)
Number of subjects: 200
Study 8077090 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (500 mg, 1 or 2 tablets every 8 h for 48 h)
Number of subjects: 200
Study 8077090 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 200
Study 3438782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (6 X 10(6) or 18 X 10(6) units)
Number of subjects: 100
Study 3438782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a
Number of subjects: 100
Study 3438782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31256650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of intravenous (IV) TXA given prior to the skin incision
Number of subjects: 186
Study 31256650 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose regimen of 1 g IV TXA given prior to skin incision and at time of wound closure
Number of subjects: 186
Study 31256650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 g IV TXA given prior to skin incision and 1 g of intraoperative topical TXA
Number of subjects: 186
Study 31256650 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of 1950 mg oral TXA given two hours preoperatively, six hours postoperatively, and on the morning of postoperative day one
Number of subjects: 186
Study 31256650 — intervention group
Group type: COMPARATOR
Intervention: All TXA regimens tested
Number of subjects: 186
Study 28944355 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate placement of 6.0 to 8.0 mm wide diameter implants (immediate group; 50 patients)
Number of subjects: 100
Study 28944355 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement of 4.0 or 5.0 mm diameter implants (delayed group; 50 patients)
Number of subjects: 100
Study 28944355 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate group
Number of subjects: 100
Study 28944355 — intervention group
Group type: COMPARATOR
Intervention: Delayed group
Number of subjects: 100
Study 26613263 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (EX/RP)
Number of subjects: 32
Study 26613263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26613263 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 32
Study 24382338 — intervention group
Group type: EXPERIMENTAL
Intervention: CoA 400 U/d plus statin
Number of subjects: 304
Study 24382338 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus statin
Number of subjects: 304
Study 22591717 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-less technique
Number of subjects: 80
Study 22591717 — intervention group
Group type: COMPARATOR
Intervention: Multiple sutures
Number of subjects: 80
Study 19772499 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 50
Study 19772499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 50
Study 17404896 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bovine collagen
Number of subjects: 275
Study 17404896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 17404896 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SF‐36 item
Number of subjects: 275
Study 17404896 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ‐DI and skin score as anchors
Number of subjects: 275
Study 15680822 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive port access mitral valve surgery (group I)
Number of subjects: 40
Study 15680822 — intervention group
Group type: COMPARATOR
Intervention: Conventional mitral valve surgery (group II)
Number of subjects: 40
Study 12101535 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast helical computed tomography (NHCT)
Number of subjects: 119
Study 12101535 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pyelography
Number of subjects: 119
Study 9987703 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 333 mg
Number of subjects: 0
Study 9987703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg
Number of subjects: 0
Study 9987703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9987703 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 7539109 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim (5 micrograms per kilogram of body weight per day)
Number of subjects: 173
Study 7539109 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 173
Study 7539109 — intervention group
Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 173
Study 2272188 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release indomethacin (75 mg)
Number of subjects: 84
Study 2272188 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release diclofenac sodium (100 mg)
Number of subjects: 84
Study 7394133 — intervention group
Group type: EXPERIMENTAL
Intervention: Start 3
Number of subjects: 34
Study 7394133 — intervention group
Group type: EXPERIMENTAL
Intervention: Start 7
Number of subjects: 34
Study 7394133 — intervention group
Group type: EXPERIMENTAL
Intervention: Finish 3
Number of subjects: 34
Study 7394133 — intervention group
Group type: EXPERIMENTAL
Intervention: Finish 7
Number of subjects: 34
Study 7394133 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TE and RT tasks)
Number of subjects: 34
Study 30612775 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic labral reconstruction
Number of subjects: 34
Study 30612775 — intervention group
Group type: COMPARATOR
Intervention: Labral repair (control)
Number of subjects: 34
Study 27492799 — intervention group
Group type: COMPARATOR
Intervention: Control implants (Osseotite) with dual acid‐etched (DAE) surface in the apical portion and a machined coronal part.
Number of subjects: 10
Study 27492799 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implants (Full Osseotite, FOSS) which were completely DAE.
Number of subjects: 10
Study 27492799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both control and test implants.
Number of subjects: 10
Study 26647864 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM self-monitoring with weekly feedback sessions
Number of subjects: 102
Study 26647864 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM self-monitoring without feedback
Number of subjects: 102
Study 26647864 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 102
Study 23262301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg t.i.d.
Number of subjects: 14
Study 23262301 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (cyproheptadine 2mg t.i.d.)
Number of subjects: 14
Study 19713300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 44
Study 19713300 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 44
Study 19815466 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon 24,000 units
Number of subjects: 32
Study 19815466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17959387 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 10
Study 17959387 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg/day)
Number of subjects: 10
Study 14551167 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 28
Study 14551167 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 28
Study 14551167 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP withdrawal
Number of subjects: 28
Study 11878058 — intervention group
Group type: EXPERIMENTAL
Intervention: lipantil 200 M
Number of subjects: 40
Study 11878058 — intervention group
Group type: COMPARATOR
Intervention: healthy men (control group)
Number of subjects: 40
Study 10052105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport games (indoor soccer and basketball)
Number of subjects: 0
Study 10052105 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiovascular fitness activities (step aerobics and running)
Number of subjects: 0
Study 7972831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast medium (iohexol)
Number of subjects: 14
Study 7972831 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast medium (ioxaglate)
Number of subjects: 14
Study 2751973 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops (1.0, 2.5, or 10 micrograms)
Number of subjects: 0
Study 2751973 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops (1.0 microgram daily or 0.5 microgram twice daily)
Number of subjects: 0
Study 2751973 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 2751973 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops (10 micrograms)
Number of subjects: 0
Study 2751973 — intervention group
Group type: EXPERIMENTAL
Intervention: PGF2 alpha‐isopropylester eye drops
Number of subjects: 0
Study 596497 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program (tutorial, home safety-proofing assignments, and follow-up)
Number of subjects: 0
Study 596497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study 30531383 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 96
Study 30531383 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control group)
Number of subjects: 96
Study 30531383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango
Number of subjects: 96
Study 28922709 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 80
Study 28922709 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 80
Study 27277189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib (200 mg single dose)
Number of subjects: 42
Study 27277189 — intervention group
Group type: COMPARATOR
Intervention: Sonidegib with esomeprazole (40 mg pre-treatment for 5 days, combination on day 6)
Number of subjects: 42
Study 22484721 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 672
Study 22484721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study 20220284 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on pregnancy and delivery (3 weeks, once a week for two hours)
Number of subjects: 0
Study 18711187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for early relapse (ER)
Number of subjects: 124
Study 18711187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for late relapse (LR)
Number of subjects: 124
Study 18711187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for MRD-negative patients
Number of subjects: 124
Study 18711187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks) for MRD-positive patients
Number of subjects: 124
Study 18711187 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy (three 35-day blocks)
Number of subjects: 124
Study 16338726 — intervention group
Group type: EXPERIMENTAL
Intervention: gym ball crunch
Number of subjects: 15
Study 16338726 — intervention group
Group type: EXPERIMENTAL
Intervention: legs raised crunch
Number of subjects: 15
Study 16338726 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 kg weight crunch
Number of subjects: 15
Study 16338726 — intervention group
Group type: EXPERIMENTAL
Intervention: standard crunch (sit-up) with bent knees
Number of subjects: 15
Study 16338726 — intervention group
Group type: EXPERIMENTAL
Intervention: roller crunch
Number of subjects: 15
Study 16338726 — intervention group
Group type: COMPARATOR
Intervention: post-fatigue (LRA and URA)
Number of subjects: 15
Study 14608279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 0
Study 10472596 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 500 mg/24 h for 3 days
Number of subjects: 101
Study 10472596 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (ACF) 500 mg/12 h for 10 days
Number of subjects: 101
Study 8671508 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF and embryo transfer
Number of subjects: 12
Study 8671508 — intervention group
Group type: COMPARATOR
Intervention: Historical comparison group (C)
Number of subjects: 12
Study 2013951 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous support of a doula
Number of subjects: 412
Study 2013951 — intervention group
Group type: COMPARATOR
Intervention: Monitoring by an inconspicuous observer
Number of subjects: 412
Study 2013951 — intervention group
Group type: COMPARATOR
Intervention: Control group (after delivery)
Number of subjects: 412
Study 6138592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 232
Study 6138592 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and steroids (Control)
Number of subjects: 232
Study 6138592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study 31912560 — intervention group
Group type: EXPERIMENTAL
Intervention: NTS curriculum (n = 21)
Number of subjects: 39
Study 31912560 — intervention group
Group type: COMPARATOR
Intervention: Control curriculum (n = 18)
Number of subjects: 39
Study 30667279 — intervention group
Group type: EXPERIMENTAL
Intervention: rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 27395
Study 28862934 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban
Number of subjects: 0
Study 28862934 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 26291648 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use (30 puffs 30 seconds apart)
Number of subjects: 30
Study 26291648 — intervention group
Group type: COMPARATOR
Intervention: Non-nicotine-containing e-cigarette
Number of subjects: 30
Study 26291648 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-containing e-cigarette
Number of subjects: 30
Study 24392086 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive medication for osteoporosis (specific medication not detailed)
Number of subjects: 30
Study 24392086 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with supportive professionals
Number of subjects: 30
Study 21725374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with auto-SCT (Arm B)
Number of subjects: 86
Study 21725374 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (Arm A)
Number of subjects: 86
Study 19652123 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline (target doses of 15 to 20 mg of olanzapine per day plus masked sertraline at 150 to 200 mg per day)
Number of subjects: 259
Study 19652123 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo (target doses of 15 to 20 mg of olanzapine per day plus masked placebo)
Number of subjects: 259
Study 19652123 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259
Study 19652123 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus sertraline and Olanzapine plus placebo
Number of subjects: 259